Pseudoephedrine Articles
Teva returns to profit, as 4th quarter 2009 sales leap 33%
16 February 2010
Czech confusion over pseudoephedrine status
16 March 2009
SCOLR decongestant delays to be "minor"
26 January 2009
Rx-to-OTC switching making comeback
21 April 2008
US FDA clears J&J's non-Rx Zyrtec
19 November 2007
Stores clear pediatric cough and cold remedies from shelves
22 October 2007
US proposal to license Internet pharmacies
26 February 2007
Australian state acts on OTC drug dealers
2 October 2006
Wyeth's revenues hit $5.2B for 1st-half 2006
31 July 2006
J&J wins bidding war for Pfizer
3 July 2006
Internet pharmacists "smuggle drugs to USA"
13 March 2006
Perrigo's fiscal-2005 sales jumps 14%
19 September 2005
Schering-Plough expands in Asia Pacific
18 July 2005
Malladi of India acquires USA's Novus
4 July 2005
SCOLR secures contract maker of 24hr-ER PSE tablets
13 June 2005
Pharmaniaga and Malladi news briefs
16 May 2005
Leiner launching phenylephrine products
25 April 2005
SCOLR to develop three new CDT drugs
22 April 2005
Barr eligible for exclusivity on generic Allegra-D
18 April 2005
Update on Barr/Aventis Allegra patent dispute
11 April 2005
FDA clears S-P's Clarinex 24 Hour
14 March 2005
IMPAX intervenes in Barr litigation
7 March 2005
SCOLR secures raloxifene-making contract
14 February 2005
SCLOR Pharma raises $15 million
14 February 2005
Barr sues FDA over generic Allegra
14 February 2005
Korean FDA bans phenylpropanolamine
9 August 2004
Aventis files new Allegra patent infringement suits
15 March 2004
Options for a P&G/Aventis link-up reviewed by broker Natexis
26 January 2004
Aventis sells pharma plant to Famar
19 January 2004
Fujisawa launches Precol as OTC rhinitis drug
5 January 2004
Aventis submits NDA for once-daily Alegra
5 January 2004
Schering-Plough settles Claritin-D patent litigation with Impax
3 November 2003
Impax' generic Claritin cleared in USA
10 February 2003
IMPAX gets initial OK for Claritin-D 24-hour
3 June 2002
S-P recalls Claritin-D lots; shares fall on concerns
25 February 2002
FDA to review IMPAX ANDA for Allegra-D generic
18 February 2002
India revises prices of 62 drug formulations
11 February 2002
UCB to post 20% profit growth in 2001
12 December 2001
Indian govt pricing moves for 103 drugs
26 November 2001
Pfizer's Zyrtec-D 12-Hour approved in USA
16 August 2001
France curbs PPA drugs, eyes cerivastatin
20 July 2001
Novartis' Tavist gains US OTC approval
13 March 2001
Chinese pharma sales, other industry data
6 February 2001
Indian price moves for 45 formulations
23 January 2001
Impax and Andrx sued by S-P over Claritin infringement
11 January 2001
IMPAX assault on Claritin bastions
15 December 2000
S-P files for new desloratadine formulations
14 December 2000
Thai drugmakers view cost of PPA ban
11 December 2000
The UK winter remedies market 2000
24 November 2000
Update - FDA asks firms to withdraw phenylpropanolamine products
9 November 2000
FDA asks companies to withdraw all phenylpropanolamine products
7 November 2000
India revises prices of six bulk drugs
15 February 2000
HMR has 10 priority projects in development
22 April 1999
Poor Rxing "Costs UK NHS L100 Mill/Year In England"
28 October 1998
Review Of US Second Qtr & Implications For Euro Firms
20 August 1998
HMR Pulls Seldane
2 January 1998
Lithuania's Sanitas To Package Zantac
10 November 1997
US OTC Makers Cite Progress With FDA
27 October 1997
Parke-Davis May Not Get GW Products
1 October 1997
HMR Launches Telfast 120 In The UK
3 March 1997
Strong Growth In 1996 As Medeva Builds In the USA
24 February 1997
HMR Pushes Allegra As It Faces Possible Seldane Ban
20 January 1997
US Methamphetamine Retail Education
18 November 1996
Fexofenadine Launched In Its First Market
2 September 1996
DEA To Ban Bulk Pseudoephedrine Sales
12 August 1996
Medeva Gains Semprex-D Rights
27 May 1996
New Malaysian Drug Registration Procedures
15 April 1996
Medeva Shows Its Strength After Failed Merger Talks
26 February 1996
Upbeat Alza Unveils Revamped Pipeline
19 February 1996
Glaxo Wellcome Sells OTC Business To Warner-Lambert
8 January 1996
US Drug Cos Reveal Strong Growth In 1995 3rd Qtr
30 October 1995
Medeva "Not For Sale" But Is On Track For Growth
24 July 1995
UK POM-To-P Switches At End-June
19 June 1995
Watson Offers $606.5 Million For Circa
10 April 1995
Medeva's 1994 Results Crown Five Years Of Growth
27 March 1995
Glaxo, Wellcome Product Lines Are Complementary
6 February 1995
S-P's Claritin-D Approved In USA
21 November 1994
RX-TO-OTC: MAKING THE DECISION TO SWITCH
18 April 1994
MEDEVA TO MARKET SEMPREX-D
11 April 1994
MYLAN ACQUIRES GENERIC SELDANE-D RIGHTS
7 March 1994
MYLAN PRODUCT ACQUISITION
14 February 1994
UK OTC SWITCHES ON JANUARY 21
17 January 1994
ANALYSTS FORECAST FDA YEAR-END APPROVALS
13 December 1993
MARKET WARMS TO COUGH & COLD SEASON IN USA
1 November 1993
NEW UK LIMITED LIST DETAILS ANNOUNCED
25 October 1993
TOXIC SHOCK FROM OTC DRUGS
27 September 1993
UK TO DELIST 62 MORE MEDICINES FROM NHS
23 August 1993
ROUND UP OF PRODUCT SWITCHES
12 July 1993
SEMPREX-D BACKED FOR HAYFEVER
17 May 1993
CIBA LAUNCHES OTC COLD PILL
19 April 1993
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
